ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced its operational and financial results for the three and six months ended June 30, 2020.
August 13, 2020
· 10 min read